2. Signaling Pathways
  3. Apoptosis
  4. Necroptosis
  5. Necroptosis Inhibitor

Necroptosis Inhibitor

Necroptosis Inhibitors (30):

Cat. No. Product Name Effect Purity
  • HY-14909
    Bardoxolone
    		Inhibitor 99.14%
    Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease.
  • HY-B1218
    Sulfaphenazole
    		Inhibitor 99.83%
    Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion.
  • HY-158312
    UH15-38
    		Inhibitor 99.80%
    UH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury.
  • HY-W010800
    Cholesteryl hemisuccinate
    		Inhibitor 99.70%
    Cholesteryl hemisuccinate is a with hepatoprotective an anticancer activity. Cholesteryl hemisuccinate inhibits Acetaminophen (AAP, HY-66005) hepatotoxicity, and prevents AAP-induced hepatic apoptosis and necrosis. Cholesteryl hemisuccinate inhibits DNA polymerase and DNA topoisomerase to inhibit DNA replication and repair and cell division. Thus, Cholesteryl hemisuccinate inhibits tumor growth.
  • HY-134050
    Apostatin-1
    		Inhibitor 99.24%
    Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (KD=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin.
  • HY-N0244
    Theaflavin-3'-gallate
    		Inhibitor 98.68%
    Theaflavin-3'-gallate is a monomer of theaflavins found in black tea, which has anti-UVB damage activity and inhibits cell apoptosis and necroptosis. Theaflavin-3'-gallate acts as a pro-oxidant and induces oxidative stress in cancer cells, inhibiting xanthine oxidase (OX), with an IC50 of 7.6 μM.
  • HY-117200
    Necrostatin-7
    		Inhibitor ≥98.0%
    Necrotatin-7 (Nec-7) is a potent necroptosis inhibitor with an EC50 of 10.6 μM. Necrotatin-7 does not inhibit recombinant RIP1 kinase.
  • HY-124546
    Necrostatin-5
    		Inhibitor 98.43%
    Necrostatin-5 (Nec-5) is a potent necroptosis inhibitor with an EC50 value of 0.24 µM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects.
  • HY-135826
    Necroptosis-IN-1
    		Inhibitor 98.39%
    Necroptosis-IN-1, an analog of Necrostatin-1, is a potent necroptosis inhibitor. Necroptosis-IN-1 is a RIPK inhibitor.
  • HY-149258
    KWCN-41
    		Inhibitor 99.83%
    KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis. KWCN-41 also has anti-inflammatory effects.
  • HY-148454
    Necroptosis-IN-3
    		Inhibitor 99.77%
    Necroptosis-IN-3 (Compound 69) is a necroptosis inhibitor that inhibits TNF-α induced necroptosis. Necroptosis-IN-3 (Compound STX1638) also inhibits 11β-HSD1.
  • HY-N3417
    Kongensin A
    		Inhibitor ≥98.0%
    Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent HSP90 inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications.
  • HY-156119
    MLKL-IN-6
    		Inhibitor 98.57%
    MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects.
  • HY-153435
    RIP1 kinase inhibitor 5
    		Inhibitor
    RIP1 kinase inhibitor 5 (example 1) is a potent inhibitor of RIP1, which is used as a checkpoint kinase to control tumor immunity. RIP1 kinase inhibitor 5 is similar with SIR1-365 (compound 13), which inhibits necrosis and iron death activity.
  • HY-162097
    RIPK1-IN-20
    		Inhibitor
    RIPK1-IN-20 (compound 13c) has a favorable RIPK1 kinase inhibition activity with an IC50 value of 59.8 nM. RIPK1-IN-20 blocks TNFα-induced necroptosis in both human and murine cells (EC50=1.06–4.58 nM).
  • HY-W010800A
    Cholesterol hemisuccinate Tris salt
    		Inhibitor
    Cholesterol hemisuccinate Tris salt (CHS-Tris) is a with hepatoprotective an anticancer activity. Cholesterol hemisuccinate Tris salt inhibits Acetaminophen (AAP, HY-66005) hepatotoxicity, and prevents AAP-induced hepatic apoptosis and necrosis. Cholesterol hemisuccinate Tris salt inhibits DNA polymerase and DNA topoisomerase to inhibit DNA replication and repair and cell division. Thus, Cholesterol hemisuccinate Tris salt inhibits tumor growth.
  • HY-144277
    RIPK1-IN-12
    		Inhibitor
    RIPK1-IN-12 is a potent RIPK1 inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC50 values of 1.6 and 2.9 nM, respectively.
  • HY-160170
    Necrosis inhibitor 3
    		Inhibitor
    Necrosis inhibitor 3 (compound B3) is a poteng inhibitor of necrosis, with the IC50 value of 0.29 nM in HT29 cells.
  • HY-155804
    RIP1 kinase inhibitor 8
    		Inhibitor
    RIP1 kinase inhibitor 8 (Compound 77) is a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor with an IC50 of 20 nM. RIP1 kinase inhibitor 8 prevents necrotic cell death. RIP1 kinase inhibitor 8 shows a favorable pharmacokinetic profile in multiple species.
  • HY-149052
    SZM-1209
    		Inhibitor
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects.